FT
First Turn Management, LLC
13F filer · CIK 0001993440Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$935MU.S. long equity reported on 13F
Positions315 new · 7 closed
Net flow last quarter-$109MBuys minus sells
Top 10 positions weight53.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202631 positions | |||||
| $77.8M | 8.32% | 0.19% | -11.3% | Q2 2024 | |
| $65.3M | 6.98% | 0.62% | +5.2% | Q3 2025 | |
| $53.5M | 5.72% | 0.42% | +15.7% | Q4 2023 | |
| $48.4M | 5.18% | 1.30% | +53.0% | Q2 2024 | |
| $47.2M | 5.05% | 0.32% | -9.0% | Q3 2024 | |
| $47.1M | 5.04% | 0.18% | +11.8% | Q4 2023 | |
| $46M | 4.92% | 0.20% | -18.9% | Q3 2025 | |
| $44.9M | 4.81% | 0.42% | +85.9% | Q4 2023 | |
| $36.2M | 3.88% | 0.62% | -23.7% | Q4 2023 | |
| $34.4M | 3.68% | 0.67% | +56.3% | Q1 2026 | |
| $30.7M | 3.28% | 1.47% | +83.3% | Q4 2025 | |
| $28.1M | 3.01% | 0.12% | +6.2% | Q2 2024 | |
| $28M | 3.00% | 0.88% | -1.1% | Q4 2025 | |
| $28M | 2.99% | 0.17% | +37.5% | Q4 2023 | |
| $28M | 2.99% | 0.30% | +96.8% | Q4 2024 | |
| $27.9M | 2.98% | 0.52% | +29.4% | Q1 2026 | |
| $25.8M | 2.76% | 0.31% | Not reported | Q4 2023 | |
| $25.5M | 2.73% | 0.34% | -45.6% | Q4 2023 | |
| $23.9M | 2.56% | 1.09% | +5.6% | Q1 2026 | |
| $23.3M | 2.49% | 0.35% | -36.4% | Q4 2025 | |
| $22.4M | 2.39% | 0.39% | +40.8% | Q1 2026 | |
| $21.8M | 2.34% | 1.95% | Not reported | Q1 2024 | |
| $19.7M | 2.11% | 0.50% | +4.3% | Q2 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $18.4M | 1.97% | 0.18% | -73.0% | Q1 2024 |
| $17.1M | 1.83% | 0.22% | Not reported | Q4 2025 | |
| $15.6M | 1.67% | 1.12% | New | Q2 2026 | |
| $14.9M | 1.60% | 0.22% | -39.2% | Q4 2025 | |
| $14.8M | 1.58% | 0.25% | New | Q2 2026 | |
| $11.8M | 1.26% | 0.12% | -59.7% | Q3 2025 | |
| $4.86M | 0.52% | 0.24% | New | Q2 2026 | |
| NNUVLNuvalent, Inc. | $3.25M | 0.35% | 0.84% | -92.9% | Q4 2023 |
| Q1 2026Reported May 15, 202633 positions | |||||
| $62.1M | 6.94% | 0.25% | +64.7% | Q3 2025 | |
| $51.9M | 5.80% | 0.59% | +22.2% | Q3 2025 | |
| $51.7M | 5.77% | 0.36% | +16.8% | Q3 2024 | |
| $45.8M | 5.11% | 0.81% | -1.6% | Q4 2023 | |
| $45.5M | 5.09% | 0.23% | -26.6% | Q2 2024 | |
| ATAPGEApogee Therapeutics, Inc. | $43.2M | 4.83% | 0.69% | +8.2% | Q1 2024 |
| $40.6M | 4.54% | 0.11% | -6.0% | Q2 2024 | |
| NNUVLNuvalent, Inc. | $37.9M | 4.24% | 11.83% | +0.5% | Q4 2023 |
| $37M | 4.13% | 0.66% | -16.8% | Q4 2023 | |
| $36.5M | 4.07% | 0.55% | +14.9% | Q4 2025 | |
| $33M | 3.68% | 0.17% | +0.3% | Q4 2023 | |
| $31.9M | 3.56% | 0.37% | -8.8% | Q4 2023 | |
| $29.1M | 3.25% | 0.99% | +20.8% | Q4 2023 | |
| $25.6M | 2.86% | 1.95% | +0.4% | Q1 2024 | |
| $24.5M | 2.73% | 1.02% | Not reported | Q2 2024 | |
| $24M | 2.69% | 0.44% | New | Q1 2026 | |
| $21.9M | 2.45% | 0.37% | -2.9% | Q4 2025 | |
| $21.2M | 2.37% | 0.31% | +23.4% | Q3 2025 | |
| $18.7M | 2.09% | 0.23% | -12.9% | Q4 2023 | |
| $18.5M | 2.07% | 0.40% | New | Q1 2026 | |
| $18.5M | 2.06% | 1.03% | New | Q1 2026 | |
| $17.9M | 2.00% | 0.48% | -37.5% | Q2 2025 | |
| $17.8M | 1.99% | 0.89% | +32.0% | Q4 2025 | |
| $17.5M | 1.95% | 0.12% | -42.1% | Q4 2023 | |
| $17.3M | 1.93% | 3.39% | +19.2% | Q4 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $17.2M | 1.92% | 0.28% | -62.5% | Q4 2025 |
| $17M | 1.90% | 0.66% | -29.9% | Q1 2024 | |
| $16.2M | 1.81% | 0.06% | +0.3% | Q3 2024 | |
| $14M | 1.57% | 0.28% | New | Q1 2026 | |
| $13.7M | 1.53% | 0.15% | +18.7% | Q4 2024 | |
| $11.5M | 1.28% | 0.88% | +24.4% | Q4 2025 | |
| $10.1M | 1.12% | 0.98% | +91.4% | Q4 2025 | |
| $5.88M | 0.66% | 0.60% | +20.2% | Q1 2025 | |
| Q4 2025Reported Feb 13, 202633 positions | |||||
| $51.4M | 5.87% | 0.49% | +30.6% | Q3 2025 | |
| $50.8M | 5.81% | 0.32% | -0.7% | Q2 2024 | |
| $46M | 5.26% | 0.12% | -17.4% | Q2 2024 | |
| $45.5M | 5.20% | 0.31% | +1.0% | Q3 2024 | |
| $38M | 4.35% | 0.93% | -15.6% | Q4 2023 | |
| $37.8M | 4.32% | 0.41% | +35.6% | Q4 2023 | |
| NNUVLNuvalent, Inc. | $37.1M | 4.24% | 11.78% | -6.6% | Q4 2023 |
| $35.8M | 4.10% | 1.00% | Not reported | Q4 2023 | |
| ATAPGEApogee Therapeutics, Inc. | $35.8M | 4.10% | 0.69% | +17.9% | Q1 2024 |
| TPTERNTerns Pharmaceuticals, Inc. | $35.2M | 4.03% | 0.78% | New | Q4 2025 |
| $31.3M | 3.58% | 0.78% | +24.6% | Q2 2025 | |
| $31M | 3.54% | 0.15% | -25.5% | Q3 2025 | |
| $30.5M | 3.48% | 0.94% | +69.7% | Q1 2024 | |
| $29.3M | 3.35% | 0.51% | New | Q4 2025 | |
| $28.1M | 3.21% | 0.21% | -9.9% | Q4 2023 | |
| $27.7M | 3.17% | 0.21% | Not reported | Q1 2025 | |
| $25.8M | 2.94% | 0.17% | +23.7% | Q4 2023 | |
| $25M | 2.86% | 0.82% | Not reported | Q4 2023 | |
| $21.5M | 2.46% | 0.68% | New | Q4 2025 | |
| $21.4M | 2.45% | 2.84% | New | Q4 2025 | |
| $20.7M | 2.36% | 0.26% | +27.8% | Q4 2023 | |
| $20.3M | 2.31% | 0.42% | New | Q4 2025 | |
| $19.6M | 2.23% | 0.04% | -40.0% | Q4 2023 | |
| $18.5M | 2.12% | 0.06% | Not reported | Q3 2024 | |
| $16.4M | 1.88% | 2.04% | -6.9% | Q1 2024 | |
| $16.1M | 1.84% | 0.25% | -25.7% | Q3 2025 | |
| $15.7M | 1.79% | 0.22% | New | Q4 2025 | |
| $15.4M | 1.76% | 0.76% | New | Q4 2025 | |
| $13.5M | 1.54% | 0.45% | New | Q4 2025 | |
| $12.2M | 1.39% | 0.40% | -61.5% | Q4 2023 | |
| $10.5M | 1.20% | 0.14% | Not reported | Q4 2024 | |
| $7.7M | 0.88% | 0.52% | New | Q4 2025 | |
| $3.46M | 0.40% | 0.50% | Not reported | Q1 2025 | |
| Q3 2025Reported Nov 14, 202529 positions | |||||
| $46.1M | 6.91% | 0.15% | -14.2% | Q2 2024 | |
| $41.8M | 6.28% | 1.11% | +8.2% | Q4 2023 | |
| $35.8M | 5.37% | 0.20% | New | Q3 2025 | |
| MMRUSMerus N.V. | $35M | 5.26% | 0.49% | +27.0% | Q2 2024 |
| NNUVLNuvalent, Inc. | $34.1M | 5.13% | 12.61% | +23.1% | Q4 2023 |
| $32.1M | 4.82% | 1.04% | +21.1% | Q4 2023 | |
| $30.6M | 4.60% | 0.31% | +6.9% | Q3 2024 | |
| $30M | 4.51% | 0.34% | +54.7% | Q2 2024 | |
| $29.1M | 4.37% | 0.24% | +8.6% | Q4 2023 | |
| $28.6M | 4.29% | 0.06% | -11.8% | Q4 2023 | |
| $26.3M | 3.95% | 1.14% | +32.8% | Q4 2023 | |
| $25.9M | 3.89% | 2.22% | +7.4% | Q1 2024 | |
| AACLXArcellx, Inc. | $25.8M | 3.87% | 0.54% | +45.8% | Q3 2024 |
| $25.5M | 3.83% | 0.18% | New | Q3 2025 | |
| $24.8M | 3.72% | 0.46% | New | Q3 2025 | |
| $20.4M | 3.06% | 0.63% | +37.6% | Q2 2025 | |
| ATAKROAkero Therapeutics, Inc. | $18.9M | 2.83% | 0.50% | +246.6% | Q2 2025 |
| $18.5M | 2.78% | 0.30% | +5.7% | Q4 2023 | |
| $16M | 2.41% | 1.32% | +53.6% | Q2 2024 | |
| ATAPGEApogee Therapeutics, Inc. | $16M | 2.40% | 0.68% | +29.3% | Q1 2024 |
| $15.7M | 2.36% | 0.39% | New | Q3 2025 | |
| $15.6M | 2.35% | 1.06% | +43.0% | Q4 2024 | |
| $14.5M | 2.18% | 0.14% | Not reported | Q4 2023 | |
| $14M | 2.10% | 0.21% | Not reported | Q4 2023 | |
| $13M | 1.95% | 0.06% | -31.5% | Q3 2024 | |
| $11.9M | 1.78% | 0.34% | -26.0% | Q3 2024 | |
| $10.3M | 1.55% | 0.56% | +14.5% | Q1 2024 | |
| $7.72M | 1.16% | 0.43% | -30.0% | Q3 2024 | |
| $1.88M | 0.28% | 0.50% | Not reported | Q1 2025 | |
Premium opens every quarter this fund has filed